Clinical trial
A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
NCT04234204 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
- Lead sponsor
- Astellas Pharma China, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 17, 2020
- Completion date
- April 20, 2022
- Enrollment
- 302 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.